Circulation

Vol. 153, Issue 5 Issue 5 2026
10
Articles

Articles in this Issue

S-Nitrosylation of Pyruvate Kinase Isoform 2 Drives Cardiac Fibrosis by Promoting Mitochondrial Fission

Shanshan Luo, Danyu Ye, Yan Zhang et al. Feb 03, 2026 pp. 338-357 10.1161/circulationaha.125.075903

BACKGROUND: Cardiac fibrosis is a major determinant of adverse clinical outcomes of many heart diseases; currently, therapeutic strategy directly targeting fibroblasts is lacking....

Efficacy of Suppression of Serum Transthyretin With Patisiran and Vutrisiran in Variant ATTR Amyloidosis: An Observational Crossover Study

Yousuf Razvi, Muhammad Umaid Rauf, Aldostefano Porcari et al. Feb 03, 2026 pp. 364-366 10.1161/circulationaha.125.076330

Evidence-Based Practices in the Cardiac Catheterization Laboratory: Invasive Epicardial Coronary Physiologic Assessment: A Scientific Statement From the American Heart Association

Sripal Bangalore, William F. Fearon, Setri Fugar et al. Feb 03, 2026 10.1161/cir.0000000000001389

Invasive epicardial coronary physiologic assessment is increasingly performed to evaluate the hemodynamic significance of intermediate coronary lesions and is recommended by guideline committees. Wher...

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

Suzanne V. Arnold, John A. Spertus, Kensey Gosch et al. Feb 03, 2026 pp. 310-318 10.1161/circulationaha.125.076542

BACKGROUND: Recent randomized trials have demonstrated that for patients with severe tricuspid regurgitation (TR), transcatheter tricuspid valve interventions (TTVI) improve patien...

Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development

Robert D. Schwab, David Degaramo, Seok Jae Hong et al. Feb 03, 2026 pp. 319-337 10.1161/circulationaha.125.073987

BACKGROUND: Cardiovascular disease caused by atherosclerosis is responsible for 18 million deaths annually, highlighting a need for new medical therapies, especially for patients w...

Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial

Chao Jiang, Zixu Zhao, Zejun Yang et al. Feb 03, 2026 pp. 297-306 10.1161/circulationaha.125.077447

BACKGROUND: Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence afte...

The Illusion of Sinus Rhythm With a Prolonged PR Interval: What Lies Beneath the Notch in V1?

Soorampally Vijay, Sreekhar Pentamsetty Feb 03, 2026 pp. 358-360 10.1161/circulationaha.125.078656

Mitochondrial Genetics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association

Jessica L. Fetterman, Patrick F. Chinnery, Rebecca McClellan et al. Feb 03, 2026 10.1161/cir.0000000000001393

Metabolic and genetic abnormalities have long been noted in cardiovascular diseases, but the contribution of mitochondrial genetic (mitochondrial DNA [mtDNA]) variation is understudied. Mitochondrial...

Artificial Intelligence–Enabled Digital Auscultation for Detecting Heart Failure With Reduced Ejection Fraction in Sub-Saharan Africa: The DAMSUN-HF Study

Alexis K. Okoh, Lambert T. Appiah, Yaw A. Wiafe et al. Feb 03, 2026 pp. 361-363 10.1161/circulationaha.125.078246

Off-Label Dapagliflozin After Atrial Fibrillation Ablation: A Reasonable Intervention or Overstretching the Evidence?

Yang Chen, Sean D. Pokorney, Gregory Y.H. Lip Feb 03, 2026 pp. 307-309 10.1161/circulationaha.125.078518

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0009-7322
E-ISSN 1524-4539
Subject Health Sciences
Language English
View Full Journal Page